Newly-Created Position to Lead Commercialisation Preparations for Lead
OXFORD, England, Sept. 18, 2012 /CNW/ - Circassia Ltd, a specialty
biopharmaceutical company focused on allergy, today announced the
appointment of Stewart Sharpe to the newly-created position of Vice
President, Commercial Operations. Mr Sharpe, who has extensive
experience of leading multinational product launches, will lead
Circassia's preparations to commercialise its lead allergy programme.
Circassia plans to begin phase III testing of its lead ToleroMune®
allergy treatment in Q4 2012.
Stewart Sharpe brings 25 years of commercial and marketing experience to
Circassia. Most recently he was Head of Commercial & Business
Development at Astellas Pharma's subsidiary OSI / Prosidion.
Previously, he held senior leadership roles at Takeda, Johnson &
Johnson, Novartis, Roche and Glaxo Wellcome. During his career he has
led the commercial activities for a number of new products, including
the global launch of Xolair® for Novartis. He also has wide experience
of establishing highly performing teams and has a proven record of
developing and implementing successful marketing strategies in several
therapeutic areas, including respiratory medicine. Mr Sharpe is a
Member of the Board of the Oxford Biosciences Network, a Member of the
UK Biotechnology Industry Association and a Member of the Chartered
Institute of Marketing.
Commenting on the appointment, Steve Harris, Circassia's CEO, said, "I am delighted to welcome Stewart to Circassia at this exciting time in the company's development. We believe our ToleroMune® technology has the potential to revolutionise allergy treatment, and as we move our lead programme into the final phase of development it is the ideal time to ramp up the extensive commercial preparations required for the successful international launch of our first product. Stewart brings to Circassia the senior-level experience and track record of achievement needed to help us achieve this ambitious goal, and we look forward to him leading our commercial preparations as
we progress our novel cat allergy treatment to the marketplace."
About Circassia's ToleroMune® allergy treatments
Circassia is developing a range of allergy treatments based on its
proprietary ToleroMune® technology. This uses small sections of
allergens (epitopes) to generate regulatory T cells that suppress
allergic responses and create immune tolerance in patients. The company
has successfully completed a number of phase II studies with its cat,
house dust mite, ragweed and grass allergy therapies. Clinical results
show that short courses of Circassia's allergy treatments can greatly
reduce patients' allergic responses, without the need for adjuvants or
other immune stimulators, while proving extremely well tolerated. As a
result, the treatments offer major potential clinical benefits compared
with existing therapies, and have significant market opportunities.
More than 150 million people suffer from allergic rhinitis in the US
and Europe, and the current treatment market is valued at approximately
$12 billion per year.
Circassia was founded in 2006 by a team of highly experienced
biotechnology scientists and entrepreneurs, and is chaired by the
former Chairman of GlaxoSmithKline, Sir Richard Sykes. The company is
based in the UK on the Oxford Science Park, and its joint venture with
McMaster University (Adiga Life Sciences Inc) is located in Hamilton,
Canada. Circassia's ToleroMune technology was developed originally by
scientists at Imperial College, London. Having successfully completed
five fundraising rounds, Circassia has raised approximately £105
million ($178 million) and is backed by a syndicate of world-class
institutional investors, including Imperial Innovations and Invesco
SOURCE: Circassia Ltd
For further information: